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AbstrACt
Objective To test the hypothesis that measles infection 
increases the incidence of non-measles infectious 
diseases over a prolonged period of time.
Design A population-based matched cohort study.
Data sources This study examined children aged 1–15 
years in The Health Improvement Network UK general 
practice medical records database. Participants included 
2228 patients diagnosed with measles between 1990 
and 2014, which were matched on age, sex, general 
practitioner practice and calendar year with 19 930 
children without measles. All controls had received at 
least one measles vaccination. Children with a history 
of immune-compromising conditions or with immune-
suppressive treatment were excluded.
Primary outcome measures Incidence rate ratio (IRR) 
of infections, anti-infective prescriptions and all-cause 
hospitalisations following measles in predetermined 
periods using multivariate analysis to adjust for 
confounding variables.
results In children with measles, the incidence rate 
for non-measles infectious disease was significantly 
increased in each time period assessed up to 5 years 
postmeasles: 43% in the first month (IRR: 1.43; 95% CI 
1.22 to 1.68), 22% from month one to the first year (IRR: 
1.22; 95% CI 1.14 to 1.31), 10% from year 1 to 2.5 years 
(IRR: 1.10; 95% CI 1.02 to 1.19) and 15% (IRR: 1.15; 
95% CI 1.06 to 1.25) in years 2.5 to 5 years of follow-
up. Children with measles were more than three times 
as likely to receive an anti-infective prescription in the 
first month and 15%–24% more likely between the first 
month and 5 years. The rate of hospitalisation in children 
with measles was increased only in the month following 
diagnosis but not thereafter (IRR: 2.83; 95% CI 1.72 to 
4.67).
Conclusion Following measles, children had increased 
rates of diagnosed infections, requiring increased 
prescribing of antimicrobial therapies. This population-
based matched cohort study supports the hypothesis that 
measles has a prolonged impact on host resistance to 
non-measles infectious diseases.
IntrODuCtIOn  
Measles is a highly contagious childhood 
disease.1 During the prevaccine era, nearly 
every child acquired measles before the 
age of 15 years.2 A key characteristic of the 
disease is a transient immune suppression, 
causing increased susceptibility to opportu-
nistic infections. As a result, measles is often 
complicated by pneumonia, diarrhoea or 
otitis media, which may lead to severe and 
even fatal disease.3 4 The introduction of 
measles-containing vaccines has reduced 
measles incidence1 as well as childhood 
mortality.5 Interestingly, this reduction in 
childhood mortality is stronger than what 
would have been expected based on measles 
mortality in unvaccinated populations.6 
strength and limitations of this study
 ► Strength: cohort represents the full range of patients 
seen in routine clinical practice in a high-income 
country.
 ► Strength: the matched study design allowed es-
timation of the effect of measles on non-measles 
infections and anti-infective prescriptions over a 
prolonged period of time.
 ► Limitation: a key assumption of the study method is 
that children with measles and children free of mea-
sles are comparable. Although major confounders 
were adjusted for, there could potentially be residual 
confounding.
 ► Limitation: the cohort was assembled according 
to the Read diagnosis code for ‘measles’ from the 
electronic medical record. Laboratory confirmation 
is lacking for most of the identified cases. Validation 
studies to identify measles and assess the accuracy 
of the date of diagnosis using this type of database 
are also lacking. As a result, some patients may 
have been misclassified.
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Although measles virus is transmitted via the respiratory 
route, it predominantly infects immune cells and causes 
systemic disease.1 7 Recent studies into the mechanism of 
measles immune suppression, based on observations in 
experimentally infected non-human primates, showed 
that measles virus preferentially replicates in CD150+ 
memory lymphocytes.8–10 It was hypothesised that viral 
cytotoxicity and immune-mediated clearance resulted in 
depletion of these cells, leading to a loss of acquired immu-
nological memory.4 9 Consistent with this hypothesis, a 
subsequent ecological study using population level data 
from England and Wales, the USA and Denmark found 
that rates of non-measles infectious disease mortality 
are tightly coupled to measles incidence—with a greater 
mortality rate at higher recent measles incidence. Mina 
et al measured a duration of measles-induced immuno-
modulation by assessing the association between measles 
incidence and childhood mortality. The results showed 
that measles was associated with increased mortality 
from other infectious diseases over a period of more 
than 2 years.11 However, the study was based on popula-
tion-level ecological association data, and the authors did 
not have access to case-based data.
Monovalent measles vaccination was introduced in 
England in 1968 and replaced in 1988 by the multivalent 
measles, mumps and rubella (MMR) vaccine. Initially, 
MMR was offered only as a single dose at the age of 12 
months. In 1996, a second dose was introduced and 
offered at age of 40 months. From 1996 to 2004, the 
number of reported measles cases in the UK was small. 
Following the publication of a subsequently discredited 
study linking autism and measles vaccination in 1998, 
coverage dropped for several years below herd protection 
level, and in 2007, measles was re-established in the UK. 
In response, an MMR catch-up campaign targeting indi-
viduals up to 18 years of age was implemented in 2008. In 
response to a mumps outbreak, Wales had already imple-
mented a national MMR vaccination campaign targeting 
individuals aged between 11 years and 25 years in 2005.
In the present study, we have used individual-level data 
from a UK database to test whether measles results in 
prolonged increased susceptibility to other infections. 
The aim of our study was to assess whether measles is asso-
ciated with increased frequency of non-measles infectious 
disease, anti-infective prescriptions or hospitalisations 
over a prolonged period of time.
MethODs
Data source
For this matched-cohort study, we used data from The 
Health Improvement Network (THIN) database. THIN is 
a population-based general practice registry that contains 
prospectively collected, anonymised longitudinal elec-
tronic patient records from over 550 general practitioner 
(GP) practices across the UK, capturing healthcare 
data from more than 12 million patients (about 6% of 
the population).12 13 Data recorded in THIN include 
demographic, socioeconomic and clinical informa-
tion, including chief complaint, symptoms, test results, 
diagnoses, prescriptions and referrals to hospitals. The 
population covered has similar demographic character-
istics to the national UK population, and the recording 
of consultations and prescriptions is comparable with 
national levels.14 15 Diagnoses and symptoms are recorded 
in Read codes, a standard terminology, maintained by 
the UK National Health Service Centre for Coding and 
Classification.16 Information on drug prescription is 
recorded using British National Formulary codes and 
the MULTILEX product dictionary. The specific codes 
used for this study were selected by a medical doctor and 
reviewed by a virologist, medical doctor and epidemiolo-
gist for their relevance (see online supplementary file S1 
for selected read codes).
study design and population
The source population consisted of all patients who had 
contributed longitudinal data to the database between 
1 January 1990 to 30 September 2014, from the age of 6 
months to 15 years. This study period captures the period 
of time when vaccination rates fell during the late 1990s, 
with increased measles cases in the following years. The 
measles group consisted of children with a measles diag-
nosis (whether or not laboratory confirmed) between the 
ages of 1 year and 15 years. The date of measles diagnosis 
was taken as the index date. To each child with a measles 
diagnosis, up to 10 children free of measles were matched 
on age in years, sex, GP practice and calendar time in 
years. Children free of measles were required to have had 
at least one dose of measles-containing vaccine, prior to 
the matched case’s index date. We considered that having 
received at least one dose of measles-containing vaccine 
would reduce the chance that children included in the 
‘free of measles’ group had ever had measles. Patients 
with a history of immune-compromising conditions (eg, 
HIV infection and organ or bone marrow transplanta-
tion), or with immune suppressive treatment prior to 
the index date were excluded (see supplementary file S2 
Table for the STROBE statement of this study).
Patient involvement
No patient was involved in setting the research question, 
outcome measures, design or conduct of the study. The 
results were not disseminated to the patients, as the study 
was based on anonymised patient records.
Outcomes
Three clinical outcomes were considered: infections, 
anti-infective prescriptions and all-cause hospitalisations. 
The outcomes were defined by the relevant clinical codes 
for symptoms and diagnoses or drug codes. Infections 
included all communicable diseases other than measles. 
Infections were required to be 14 days apart to be consid-
ered a new event. Anti-infective prescriptions included 
all systemic antibiotics, antimycotic, antivirals and anti-
parasitic medication. For anti-infective prescriptions and 
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hospitalisations, any event occurring on a different day 
(at least 1 day apart) was considered a new event.
Follow-up
Follow-up started at the index date and continued for 
a period of 5 years, until date of transfer out the GP’s 
practice, the 15th birthday or death, whichever came 
earliest. Each outcome was analysed in predetermined 
periods following measles diagnosis: within the first 
month; ≥1 month to <1 year; ≥1 year to <2.5 years; and ≥2.5 
years to <5 years, to observe changes over time. HRs for 
hospitalisation were calculated with follow-up starting at 
30 days after the index date to avoid inclusion of hospi-
talisations due to initial complications related to measles.
Potential confounders and effect modifiers
We considered as potential confounders: chronic respi-
ratory disease, cardiovascular disease, prior exposure to 
routine childhood vaccines other than measles containing 
vaccines, deprivation index, healthcare consumption and 
occurrence of each outcome of interest in the year prior 
to index. Potential confounders were assessed at the index 
date. Vaccine adherence was defined as exposure to any 
dose of other routine childhood vaccines such as pertus-
sis-containing vaccines before the index date and coded 
as binary with vaccine adherence equal to one if any other 
childhood vaccine was received and zero otherwise. The 
Townsend deprivation score, a measure of social depri-
vation based on unemployment level, car ownership, 
home ownership and household overcrowding levels by 
area, was used within a particular zip code.17 Healthcare 
consumption, as a proxy for general health, was assessed 
by the rate of GP consultations in the year prior to the 
index date18 and categorised using quintile cut-off points. 
For a list of various types of consultations included to 
calculate GP consultation rate, see online supplementary 
file S3. For each outcome, the event rate in the year prior 
to index was calculated.
statistical analysis
Baseline characteristics were compared between chil-
dren with measles and children free of measles using 
Student’s t-test, Mann-Whitney U test, χ2 test or Fisher’s 
exact test as appropriate. Observed incidence rates of 
measles diagnosis codes as well as measles notification 
codes were estimated by dividing the number of cases 
by the number of person-years at risk within the data-
base stratified by calendar year and were compared with 
expected incidence rates, derived from publicly avail-
able official statistics from the UK National Archives.19 
The differences in incidence of the outcomes between 
children with measles and children free of measles were 
analysed for each period using Poisson regression. For 
this analysis, matching was relaxed due to uninforma-
tive matched strata for each outcome, with over 1000 
uninformative strata for the hospitalisation outcome. A 
stratified analysis was therefore not conducted, and the 
analysis was adjusted for confounding using multivariable 
analysis. We submitted the following confounders: history 
of cardiovascular malformation, history of respiratory 
disease, exposure to childhood vaccinations other than 
measles containing vaccination, age, sex and GP consul-
tation rate. Exposure to childhood vaccinations other 
Figure 1 Flow chart of study cohort selection. Starting from 1 070 365 eligible children in the THIN database, 2228 measles 
patients and 19 930 matched controls were selected for this study. THIN, The Health Improvement Network.
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Table 1 Baseline characteristics of enrolled subjects
Variable Category
Measles group (n=2228) Non-measles group (n=19 930)
P valueMean±SD or N (%)
Median 
(IQR) Mean±SD or N (%)
Median 
(IQR)
Age at case diagnosis 3.06±3.04 2 (1–4) 3.16±3.01 2 (1–4) 0.1264
Person time (days) 1379.9±595.33 1826 (849–
1826)
1358.7±611.54 1826 (804–
1826)
0. 1186
Sex Female 1038 (46.59) 9275 (46.54) 0.9643
Region England 1816 (81.51) 16 291 (81.74) 0.9871
Northern 
Ireland
52 (2.33) 448 (2.25)
Scotland 167 (7.50) 1497 (7.51)
Wales 193 (8.66) 1695 (8.50)
Experience of an 
excluding event during 
follow-up
125 (5.61) 898 (4.51) 0.0219
History of respiratory 
disease
84 (3.77) 737 (3.70) 0.8592
History of cardiovascular 
disease
18 (0.81) 124 (0.62) 0.3249
Townsend deprivation 
score
0 108 (4.85) 1001 (5.02) 0.1696
1 482 (21.63) 4553 (22.84)
2 409 (18.36) 3483 (17.48)
3 422 (18.94) 3947 (19.80)
4 426 (19.12) 3727 (18.70)
5 381 (17.10) 3198 (16.05)
Missing 0 (0.00) 21 (0.11)
Vaccine non-adherence Yes 43 (1.93) 29 (0.15) <0.0001
Measles vaccination 
before index date
1212 (54.40) 19 930 (100.00) <0.0001
Measles vaccination 
ever during observation
2044 (91.74) 19 930 (100.00) <0.0001
# Consults in the 
year before Index 
(continuous)
13.87±11.54 11 (6–19) 13.22±13.80 10 (5–17) <0.0001
# Consults in the 
year before Index 
(categorical)
0–3 300 (13.46) 3731 (18.72) <0.0001
4–7 427 (19.17) 4193 (21.04)
8–11 443 (19.88) 3546 (17.79)
12–19 542 (24.33) 4406 (22.11)
>19 516 (23.16) 4054 (20.34)
Infections in the year 
prior to index
0.86±1.27 1 (0–2) 0.87±1.58 1 (0–2) 0.7782
Anti-infectives in the 
year prior to index
1.58±1.97 0 (0–1) 1.53±2.41 0 (0–1) 0.2708
Hospitalisations in the 
year prior to index
0.11±0.51 0 (0–0) 0.07±0.41 0 (0–0) 0.0004
P values lower than 0.05 are shown in bold.
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than measles-containing vaccination was not retained 
in final models. In addition, per outcome, we submitted 
rate of the outcome in the year prior to the index date. 
Absolute rates of each outcome per 1000 person-days 
were calculated with covariates fixed as follows: cardio-
vascular and respiratory history=no; receipt of other 
childhood vaccines=yes; number of consults and events 
in the previous year=median; age=3 years; and sex=fe-
male. Kaplan-Meier curves and log-rank tests were used to 
compare time with first hospitalisation between measles 
infected and control individuals, with follow-up begin-
ning at 30 days after the index date (to avoid including 
codes related to the initial measles infection). A stratified 
Cox proportional hazards model, stratified by matched 
set and adjusted for confounding variables, was applied 
to estimate HRs comparing children with measles and 
children free of measles. Assumptions of proportional 
hazards were assessed by inspecting the Kaplan-Meier 
curves and formally tested with inspection of a measles*-
time interaction term. Model selection was by backward 
covariate selection, with the criteria p<0.1. Subsequently, 
we verified automatically selected models using minimi-
sation of Akaike’s Information Criterion (AIC). We also 
estimated the HRs for the outcomes first infection and 
first prescription.
sensitivity analysis
Children who have received vaccinations may be different 
in their underlying health status, social background, 
lifestyle, healthcare-seeking behaviour and healthcare 
utilisation from those who did not receive vaccinations. 
To examine the possible effect of these unmeasured 
confounders, we conducted a sensitivity analysis, strati-
fying the data into matched sets in which all measles cases 
had received (ie, non-measles group vaccinated vs measles 
group vaccinated) or had not received a measles-con-
taining vaccine (ie, non-measles group vaccinated vs 
measles-group unvaccinated). In post hoc analyses, we 
assessed the incidence rate ratio (IRR) of each outcome 
over the entire study period in vaccine adherent versus 
non-adherent children for each outcome using Poisson 
regression. We also examined the correlation of the 
consultation rate the year before and after the index date 
in measles versus control groups using linear regression. 
For data management and analysis, we used SAS V.9.3.
results
From the database population of 1 070 365 children 
aged 1–15 years, we identified 2228 eligible children 
with a measles diagnosis. These children were matched 
to 19 930 children free of measles. Figure 1 illustrates 
the composition of the study cohort. Table 1 describes 
baseline characteristics of children with measles and 
children free of measles. Median follow-up time was 5.0 
years (IQR: 2.2–5.0). The incidence rate of measles and 
of measles notification as reported in the THIN database 
were similar to the expected overall confirmed measles 
incidence rate as reported by official UK Government 
Figure 2 Consultations in measles patients and matched controls. Incidence rates of consultations in children diagnosed with 
measles (blue lines) or matched controls (red lines) per 10 person-years, plotted by time (in months) before or after diagnosis of 
measles. The vertical dotted line indicates the time point of diagnosis in the measles patients. The shaded areas represent 95% 
CIs.
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statistics (see supplementary file S4 figure). However, 
between 1999 and 2006 diagnoses in THIN decrease while 
notifications and the population incidence increase. 
There was no significant difference in follow-up time 
between the children with measles and the children free 
of measles. Exposure to childhood vaccines other than 
measles-containing vaccines prior to the index date was 
lower among children with measles (98.1% vs 99.8%), but 
this difference was small compared with the difference 
in vaccination coverage of measles-containing vaccines 
prior to the index date (54.4% in children with measles 
vs 100% in children free of measles, due to inclusion 
criteria). GP consultation rate in the year prior to index 
date was slightly higher in the measles group than in the 
non-measles group: mean 13.87 versus 13.22 (p<0.001) 
consults in the year prior, respectively (figure 2). The 
Townsend deprivation index was similar in children with 
measles and children free of measles. The rate of infec-
tions and anti-infective prescriptions prior to index were 
similar between measles and non-measles subjects, while 
hospitalisations prior to index were more frequent for 
subjects subsequently diagnosed with measles. Table 2 
describes events of interest occurring during follow-up in 
measles and non-measles subjects.
Infectious disease
The most frequently occurring infectious diseases were 
upper respiratory infectious diseases (for details see 
online Supplementary file S5 table). The IRR (table 3) of 
infections for children with measles compared with chil-
dren free of measles was 43% higher in the first month 
(IRR: 1.43; 95% CI 1.22 to 1.68), 22% higher from the first 
month to the first year (IRR: 1.22; 95% CI 1.14 to 1.31), 
10% higher from the first year to 2.5 years (IRR: 1.10; 
95% CI 1.02 to 1.19) and 15% higher (IRR: 1.15; 95% CI 
1.06 to 1.25) in the 2.5–5 years of follow-up (figure 3).
The absolute rate of infections per 1000 person-days in 
the first month to first year was 1.7 (95% CI 1.6 to 1.9) for 
children with measles and 1.33 (95% CI 1.29 to 1.36) for 
children free of measles. The adjusted HR for non-mea-
sles infectious disease over the full follow-up period 
starting 30 days after measles diagnosis was 1.20 (95% CI 
1.13 to 1.28) (see online Supplementary file S6).
Prescriptions
Children with measles received more anti-infective 
prescriptions than children without measles in all 
periods (table 3, figure 4, online Supplementary file 
S5 and Supplementary file S7). The absolute rate of 
Table 2 Descriptive statistics of events in enrolled measles exposed and measles-non exposed children
Variable Category
Measles group (n=2228) Non-measles group (n=19 930)
P valuesMean±SD or N (%)
Median 
(IQR) Mean±SD or N (%)
Median 
(IQR)
# Infections (continuous) 1. 61±2.17 1 (0–2) 1.28±1.85 1 (0–2) <0.0001
# Infections (categorical) 0 864 (38.78) 9224 (46.28) <0.0001
1–2 856 (38.42) 7184 (36.05)
3–5 377 (16.92) 2852 (14.31)
6–10 115 (5.16) 591 (2.97)
>10 16 (0.72) 79 (0.40)
# Anti-infective Rx 
(continuous)
4.58±5.45 3 (1–6) 3.35±4.43 2 (0–5) <0.0001
# Anti-infective Rx 
(categorical)
0 326 (14.63) 5104 (25.61) <0.0001
1–2 631 (28.32) 6168 (30.95)
3–5 651 (29.22) 4617 (23.17)
6–10 393 (17.64) 2892 (14.51)
11–20 187 (8.39) 979 (4.91)
>20 40 (1.80) 170 (0.85)
# Hospitalisations 
(continuous)
0.16±0.74 0 (0–0) 0.12±0.63 0 (0–0) 0.0001
# Hospitalisations 
(categorical)
0 1999 (89.72) 18 369 (92.17) 0.0014
1–2 204 (9.16) 1396 (7.00)
3–5 20 (0.90) 134 (0.67)
6–10 3 (0.13) 24 (0.12)
>10 2 (0.09) 7 (0.04)
Rx, drug treatment.
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anti-infective prescriptions per 1000 person-days in the 
first month to first year was 0.55 (95% CI 0.51 to 0.59) 
for children with measles and 0.45 (95% CI 0.43 to 0.47) 
for children free of measles. The adjusted HR for anti-in-
fective prescription over the full follow-up period starting 
30 days after measles diagnosis was 1.24 (95% CI 1.18 
to 1.31). Within the first month of follow-up, children 
with measles had more than a threefold increase in use 
of anti-infective drugs as compared with controls (IRR: 
3.60; 95% CI 3.31 to 3.91). Following the first month, 
children who had measles continued to use more anti-in-
fective drugs over the entire duration of the follow-up: 
1 month–1 year (IRR 1.24; 95% CI 1.18 to 1.32); 1 year–
2.5 years (IRR 1.21; 95% CI 1.13 to 1.29) and 2.5 years–5 
years (IRR 1.15; 95% CI 1.07 to 1.24).
hospitalisation
Despite smaller sample sizes, the analysis on hospitalisations 
also showed increased IRRs, although these were significant 
during the first period only (figure 5). In the Cox propor-
tional hazards model, confounder selection using either 
backward selection, or minimisation of the AIC resulted in 
the same model, namely control for the hospitalisation rate 
prior to the index date, the GP consultation rate in the year 
prior to index date and history of cardiac malformation. The 
absolute rate of hospitalisations per 1000 person days in the 
first month to first year was equal at 0.2 (95% CI 0.1 to 0.2) 
for children with measles and children free of measles. The 
adjusted HR of hospitalisation for measles versus non-mea-
sles subjects was 1.12 (95% CI 0.96 to 1.31).
sensitivity analysis
Results of the sensitivity analysis were partially in agreement 
with findings from the main analysis. When we restricted the 
analysis to only those children who had received measles 
vaccination prior to receiving a diagnosis of measles (54.4% 
of all eligible children with a measles diagnosis), differences 
to the main analyses were not observed for anti-infective 
prescriptions. However, an increased rate of hospitalisations 
was no longer detected in any time period and an increased 
rate of infections no longer extended beyond 1 year postdi-
agnosis. In the analysis restricted to those children who had 
not had a measles vaccination prior to receiving a diagnosis 
of measles (45.6% of all eligible children with a measles 
diagnosis), the results were in line with the main findings for 
hospitalisations, infections and anti-infective prescriptions 
Table 3 Incidence rate ratios (IRRs) of events of interest in predefined time periods following measles infection
Time period Analysis*
IRR (95% CI)
Infections
Anti-infective 
prescriptions Hospitalisation
Days 0–31 Primary 1.43 (1.22 to 1.68) 3.60 (3.31 to 3.91) 2.83 (1.72 to 4.67)
Unadjusted 1.57 (1.34 to 1.84) 3.77 (3.48 to 4.08) 3.24 (2.03 to 5.19)
Sensitivity (vaccinated 
measles subjects only)
1.47 (1.17 to 1.86) 4.65 (4.20 to 5.14) 1.92 (0.89 to 4.14)
Sensitivity (unvaccinated 
measles subjects only)
1.33 (1.07 to 1.65) 2.45 (2.12 to 2.82) 3.30 (1.60 to 6.82)
Days 32–365 Primary 1.22 (1.14 to 1.31) 1.25 (1.18 to 1.32) 1.14 (0.88 to 1.48)
Unadjusted 1.31 (1.21 to 1.41) 1.31 (1.24 to 1.39) 1.29 (0.94 to 1.77)
Sensitivity (vaccinated 
measles subjects only)
1.15 (1.04 to 1.27) 1.25 (1.16 to 1.35) 0.95 (0.61 to 1.46)
Sensitivity (unvaccinated 
measles subjects only)
1.26 (1.15 to 1.39) 1.24 (1.15 to 1.35) 1.29 (0.92 to 1.81)
Days 366–
913
Primary 1.10 (1.02 to 1.19) 1.21 (1.13 to 1.29) 1.08 (0.80 to 1.47)
Unadjusted 1.15 (1.06 to 1.24) 1.25 (1.17 to 1.34) 1.19 (0.85 to 1.66)
Sensitivity (vaccinated 
measles subjects only)
1.10 (0.99 to 1.22) 1.21 (1.11 to 1.32) 1.26 (0.79 to 2.04)
Sensitivity (unvaccinated 
measles subjects only)
1.09 (0.99 to 1.21) 1.22 (1.12 to 1.34) 0.93 (0.64 to 1.35)
Days 914–
1826
Primary 1.15 (1.06 to 1.25) 1.15 (1.07 to 1.24) 1.24 (0.92 to 1.67)
Unadjusted 1.23 (1.13 to 1.35) 1.22 (1.13 to 1.31) 1.38 (1.07 to 1.78)
Sensitivity (vaccinated 
measles subjects only)
1.06 (0.94 to 1.20) 1.25 (1.13 to 1.37) 1.08 (0.76 to 1.54)
Sensitivity (unvaccinated 
measles subjects only)
1.21 (1.07 to 1.35) 1.07 (0.96 to 1.19) 1.37 (0.87 to 2.17)
*Primary and sensitivity analyses were adjusted for: frequency of consultations in the year prior to index, frequency of the outcome of interest 
in the year prior to index, history of cardiovascular malformation, history of respiratory disease, age and sex.
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with the exception that increased risk for anti-infective 
prescriptions did not extend into the period 2.5–5 years 
following measles.
Post hoc analysis of the impact of vaccine adherence 
regardless of measles status revealed that vaccine non-ad-
herent children were 42% more likely to receive an anti-in-
fective prescription than vaccine-adherent children. There 
was no difference in risk of infections or hospitalisations. 
Regressing postindex consults on preindex consults and 
measles, or non-measles status revealed that both groups 
showed similar trends with the rate of consultation before 
index date higher than that after the index date.
DIsCussIOn
To our knowledge, this is the first matched-cohort study 
to investigate the longevity of measles-associated immune 
suppression in a high-income country. The results of this 
study are in strong agreement with previous non-clinical 
and ecological studies also in high-income countries.11 
We found that rates of diagnosed infections and anti-in-
fective prescriptions are elevated following measles infec-
tion for up to 5 years. While increased risk of infections 
and anti-infective prescriptions remained statistically 
significant over the full 5-year study period, the effect size 
diminished particularly after the first year, and statistical 
significance is partly explained by our large sample size. 
Children diagnosed with measles were hospitalised more 
frequently than children free of measles, although this 
was only significant in the first month following infec-
tion. When we excluded the first month postmeasles, the 
time to first hospitalisation did not differ between the 
measles group and the non-measles group. This could be 
explained, at least in part, by a survival bias, whereby a 
disproportionately large number of measles cases entered 
the hospital during the first month, and these may have 
represented the most severe cases. Additionally, a lack of 
effect on hospitalisation after the first month was likely a 
result of the low overall number of hospitalisations in our 
cases and controls. We acknowledge that the first interval 
spanning 1 month–1 year postmeasles is wide and have 
conducted analysis using smaller intervals, the results of 
which can be found in the supplementary material (see 
online Supplementary file S8 table). These results are in 
agreement with our primary analysis, with risk of infec-
tions and anti-infectives remaining elevated throughout 
the entirety of the first year following measles and risk 
of hospitalisations elevated in the first month following 
measles only.
The incidence rates of infections, anti-infective prescrip-
tions and hospitalisations in the measles group appear to 
Figure 3  | Infections in measles patients and matched controls. Incidence rates of infections in children diagnosed with 
measles (blue lines) or matched controls (red lines) per 10 person-years, plotted by time (in months) before or after diagnosis of 
measles. The vertical dotted line indicates the time point of diagnosis in the measles patients. The shaded areas represent 95% 
CIs.
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increase prior to the index date, that is, before they got 
measles (figures 3–5). This could partially be explained 
by a lag time between a suspected diagnosis and a defi-
nite diagnosis. In some instances, a GP may have coded 
a definite diagnosis on the date a confirmation had been 
received either from the lab or from the hospital. For 
some outcomes, however, the rise in incidence begins 
months before diagnosis. Validation studies to assess the 
accuracy of the date of diagnosis using this type of data-
base are lacking.
To be considered a new event, prescriptions only had to 
be given on a different day. Acknowledging that a prescrip-
tion can be changed if there is poor response or allergy 
to the first drug, we also examined the effect of anti-infec-
tive prescription, considering a 14-day interval between 
anti-infective prescriptions. This did not change the signif-
icance or direction of any result (results not shown). Both 
groups revealed similar trends with the rate of consulta-
tion before index date higher than after index date.20 21 
This is most likely related to age. Although measles is a 
statutory notifiable infectious disease under EU legisla-
tion,22 an under-reporting of (severe) cases, who might 
have by-passed the GP and gone directly to the hospital, 
cannot be ruled out. Also, it is possible that a mild measles 
infection would not have prompted a visit to the GP and 
may have gone undetected as well.23 24 This means that we 
may have missed some children with measles. It should 
be noted though that laboratory confirmation for most of 
the identified cases is lacking. As a result, some patients 
may have been misclassified. Validation studies to accu-
rately identify measles using this type of database are also 
lacking. In case of non-differential misclassification, the 
direction of the bias is likely to be towards the null value, 
so one would expect to see a larger estimate if misclassi-
fication was absent. Differential misclassification however 
can inflate or attenuate the effect estimates. To minimise 
the impact of differential misclassification, we examined 
the consultation rate in both measles and non-measles 
groups. To provide additional assurance that controls 
were children truly free of measles, controls had to have 
at least one measles-containing vaccination prior to the 
index date. An advantage of this type of observational 
study is that it is not necessary to identify all outcomes 
in all children in order to obtain an unbiased estimate. 
A key assumption, however, is comparability of children 
with measles and children free of measles. In order to 
ensure that the children with measles and the children 
free of measles were comparable, we matched them on 
confounding factors such as age, sex, GP practice and 
calendar time. We also considered including experiencing 
an excluding event (ie, an immune-compromising condi-
tion or immune suppressive treatment) as a censoring 
Figure 4  | Anti-infective prescriptions in measles patients and matched controls. Incidence rates of anti-infective prescriptions 
in children diagnosed with measles (blue lines) or matched controls (red lines) per 10 person-years, plotted by time (in months) 
before or after diagnosis of measles. The vertical dotted line indicates the time point of diagnosis in the measles patients. The 
shaded areas represent 95% CIs.
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variable but determined this was not consistent with our 
matching strategy: the groups were matched to be compa-
rable at index. Nevertheless, we acknowledge that it is 
possible that confounding due to differences in under-
lying health status, social background, lifestyle, health 
seeking behaviour and healthcare utilisation between 
children with measles and children free of measles may 
have occurred. The complexity of these factors makes 
them difficult to control. We attempted to overcome 
the confounding effect of underlying health status by 
excluding children with a history of immune-compro-
mising conditions, and controlling for comorbidities 
such as cardiovascular disease, and respiratory disease. 
We assessed social background and lifestyle by testing 
for differences in social deprivation within a particular 
zip code and matching on practice. Certain children 
may have had a lower threshold for visiting the GP and 
therefore may have had a higher likelihood of receiving a 
diagnosis of measles (particular during an outbreak) and 
may also have been diagnosed more frequently with other 
infectious diseases and/or may have received a prescrip-
tion for anti-infectives more frequently. To investigate 
this, we included GP consultation rate in the year prior 
to cohort entry as a covariate in each of our models. In 
the unmatched Poisson analyses, we did not control for 
all potential confounders. Because 472 unique practices 
were represented in the cohort, it was impossible to 
control for practice. Similarly, the 25 years included in 
the study period make control for calendar year infea-
sible unless calendar year is treated as a continuous vari-
able, which would require the assumption of a linear 
relationship between year and log(events). To address 
the potential effect of calendar time, we have conducted 
analyses stratified by calendar period (before 2005 and 
after 2004) and included these results in supplementary 
material (see online Supplementary file S9 table).
Because vaccinated and unvaccinated children may 
differ in their health-seeking behaviour or likelihood of 
acquiring infectious disease, we conducted a sensitivity 
analysis in two strata: (1) restricting to only those chil-
dren who had received a measles vaccination prior to the 
index date and (2) restricting to only those children who 
were unexposed to measles vaccination prior to the index 
date. Results from both subanalyses were in line with the 
findings from the main analysis with the exceptions that 
the period of increased risk for infections did not extend 
past 1 year and no increased risk for hospitalisations was 
detected when analysis was limited to measles-vaccinated 
children.
We did not adjust for measles vaccination after index 
date in the context of postexposure prophylaxis because 
many exposed persons are not identified until more 
Figure 5  | Hospitalisations in measles patients and matched controls. Incidence rates of hospitalisations in children 
diagnosed with measles (blue lines) or matched controls (red lines) per 10 person-years, plotted by time (in months) before or 
after diagnosis of measles. The vertical dotted line indicates the time point of diagnosis in the measles patients. The shaded 
areas represent 95% CIs.
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than 72 hours after initial exposure, which is too late for 
prophylaxis with measles vaccine.2 Post hoc analysis of 
vaccine adherent versus non-adherent children revealed 
an increased rate of anti-infective prescriptions in non-ad-
herent children but no difference for other outcomes.
We conclude that our results support the hypothesis 
that infection with measles is associated with long-term 
increased risk of other infectious diseases and that 
by preventing measles, vaccination is associated with 
non-specific heterologous improvements in health. 
However, because all of the non-measles controls received 
vaccination, we cannot rule out a direct benefit of vacci-
nation to boost heterologous immune function, as has 
been suggested.25 26 Nonetheless, the results fit with what 
would be expected from animal models and what has 
been shown in ecological studies and warrant further 
investigation into the long-term consequences of viral 
infections, particularly those with heightened tropism for 
immune memory cells on host resistance.
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